Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy
- PMID: 14981738
- DOI: 10.1002/mus.10559
Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy
Abstract
Oxaliplatin, a platinum-based chemotherapeutic agent, is effective in the treatment of solid tumors, particularly colorectal cancer. During and immediately following oxaliplatin infusion, patients may experience cold-induced paresthesias, throat and jaw tightness, and occasionally focal weakness. We assessed nerve conduction studies and findings on needle electromyography of patients with metastatic colorectal cancer before and during treatment with oxaliplatin. Twenty-two patients had follow-up studies within 48 h following oxaliplatin infusions, and 14 patients had follow-up studies after 3-9 treatment cycles. Repetitive compound muscle action potentials and neuromyotonic discharges were observed in the first 24-48 h following oxaliplatin infusion, but resolved by 3 weeks. After 8-9 treatment cycles, sensory nerve action potential amplitudes declined, without conduction velocity changes or neuromyotonic discharges. The acute neurological symptoms reflect a state of peripheral nerve hyperexcitability that likely represents a transient oxaliplatin-induced channelopathy. Chronic treatment causes an axonal neuropathy similar to other platinum-based chemotherapeutic agents.
Similar articles
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
Oxaliplatin-induced neurotoxicity and the development of neuropathy.Muscle Nerve. 2005 Jul;32(1):51-60. doi: 10.1002/mus.20340. Muscle Nerve. 2005. PMID: 15880395
-
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.J Clin Oncol. 2009 Mar 10;27(8):1243-9. doi: 10.1200/JCO.2008.19.3425. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164207
-
Oxaliplatin-associated neuropathy: a review.Ann Pharmacother. 2005 Jan;39(1):128-35. doi: 10.1345/aph.1E319. Epub 2004 Dec 8. Ann Pharmacother. 2005. PMID: 15590869 Review.
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
Cited by
-
Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).Support Care Cancer. 2016 Dec;24(12):5059-5068. doi: 10.1007/s00520-016-3373-1. Epub 2016 Aug 18. Support Care Cancer. 2016. PMID: 27534963 Free PMC article.
-
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.Cancer Treat Rev. 2013 Feb;39(1):27-43. doi: 10.1016/j.ctrv.2012.03.007. Epub 2012 Apr 19. Cancer Treat Rev. 2013. PMID: 22520262 Free PMC article. Review.
-
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.World J Surg Oncol. 2013 Jan 25;11:19. doi: 10.1186/1477-7819-11-19. World J Surg Oncol. 2013. PMID: 23351188 Free PMC article. Clinical Trial.
-
Selective cold pain inhibition by targeted block of TRPM8-expressing neurons with quaternary lidocaine derivative QX-314.Commun Biol. 2018 May 31;1:53. doi: 10.1038/s42003-018-0062-2. eCollection 2018. Commun Biol. 2018. PMID: 30271936 Free PMC article.
-
The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy.Sci Rep. 2019 Dec 30;9(1):20361. doi: 10.1038/s41598-019-56969-9. Sci Rep. 2019. PMID: 31889149 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
